2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3
Meza L, McDermott D, Escudier B, Hutson T, Porta C, Verzoni E, Atkins M, Kasturi V, Pal S, Rini B. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3. The Oncologist 2022, 28: e167-e170. PMID: 36576430, PMCID: PMC10020797, DOI: 10.1093/oncolo/oyac255.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAxitinibCarcinoma, Renal CellHumansKidney NeoplasmsPhenylurea CompoundsSorafenibConceptsMetastatic renal cell carcinomaProgression-free survivalRenal cell carcinomaTIVO-3Cell carcinomaResponse rateEvaluate PFSAdvanced renal cell carcinomaTreated with axitinibTreatment of patientsClinical efficacyIdentified patientsSubgroup analysisTivozanibAxitinibPatientsCarcinomaSorafenibTreatmentMonthsSubgroupsTrialsTherapySurvivalDrug
2020
Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe
Meza L, Bergerot P, Agarwal N, Pal S. Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe. Annals Of Oncology 2020, 32: 12-14. PMID: 33121996, DOI: 10.1016/j.annonc.2020.10.481.Commentaries, Editorials and Letters